Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours.

× No keyword cloud information.

12 in total

1. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy.

Authors: S Moll; V Nickeleit; J Mueller-Brand; F P Brunner; H R Maecke; M J Mihatsch
Journal: Am J Kidney Dis Date: 2001-04 Impact factor: 8.860

2. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study.

Authors: C Waldherr; M Pless; H R Maecke; A Haldemann; J Mueller-Brand
Journal: Ann Oncol Date: 2001-07 Impact factor: 32.976

3. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

Authors: Christian Waldherr; Miklos Pless; Helmut R Maecke; Tilmann Schumacher; Armin Crazzolara; Egbert U Nitzsche; Andreas Haldemann; Jan Mueller-Brand
Journal: J Nucl Med Date: 2002-05 Impact factor: 10.057

4. 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion.

Authors: François Jamar; Raffaella Barone; Isabelle Mathieu; Stéphan Walrand; Daniel Labar; Pascal Carlier; Joëlle de Camps; Horst Schran; TianLing Chen; M Charles Smith; Hakim Bouterfa; Roelf Valkema; Eric P Krenning; Larry K Kvols; Stanislas Pauwels
Journal: Eur J Nucl Med Mol Imaging Date: 2003-02-12 Impact factor: 9.236

5. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy.

Authors: S Froidevaux; A Heppeler; A N Eberle; A M Meier; M Häusler; C Beglinger; M Béhé; P Powell; H R Mäcke
Journal: Endocrinology Date: 2000-09 Impact factor: 4.736

6. Is the renal dosimetry for [90Y-DOTA0,Tyr3]octreotide accurate enough to predict thresholds for individual patients?

Authors: Mark W Konijnenberg
Journal: Cancer Biother Radiopharm Date: 2003-08 Impact factor: 3.099

7. Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide.

Authors: Marion De Jong; Roelf Valkema; Arthur Van Gameren; Hester Van Boven; Axel Bex; Eric Pieter Van De Weyer; Jan Dirk Burggraaf; Meike Körner; Jean-Claude Reubi; Eric P Krenning
Journal: J Nucl Med Date: 2004-07 Impact factor: 10.057

8. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate.

Authors: Jaap J M Teunissen; Dik J Kwekkeboom; Eric P Krenning
Journal: J Clin Oncol Date: 2004-07-01 Impact factor: 44.544

9. 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies.

Authors: G Paganelli; L Bodei; D Handkiewicz Junak; P Rocca; S Papi; M Lopera Sierra; M Gatti; M Chinol; M Bartolomei; M Fiorenza; C Grana
Journal: Biopolymers Date: 2002 Impact factor: 2.505

10. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate.

Authors: D J Kwekkeboom; W H Bakker; B L Kam; J J M Teunissen; P P M Kooij; W W de Herder; R A Feelders; C H J van Eijck; M de Jong; A Srinivasan; J L Erion; E P Krenning
Journal: Eur J Nucl Med Mol Imaging Date: 2003-01-09 Impact factor: 9.236

1 in total

Review 1. A review on the clinical uses of SPECT/CT.

Authors: Giuliano Mariani; Laura Bruselli; Torsten Kuwert; Edmund E Kim; Albert Flotats; Ora Israel; Maurizio Dondi; Naoyuki Watanabe
Journal: Eur J Nucl Med Mol Imaging Date: 2010-02-25 Impact factor: 9.236

1 in total